[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
4.3 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]

Apple Might Launch Its Own Smart Home Camera As It Focuses On Providing A More Integrated Product Experience For Its Users

Apple is increasingly focusing on building its own devices and expanding its ecosystem by taking steps towards a more native experience for users and relying less on third-party accessories. While the Cupertino-based tech giant's HomePod and AppleTV have left quite the mark in the smart home category, it generally relies more on outsourcing cameras and other hardware for smart homes. Now, a new report suggests that the company intends to create a fully integrated experience by developing its own smart home accessories. Gurman hints about Apple working on making smart home products like security cameras for a more integrated experience […]

Best of Black Friday 2024 – power stations and bundles: Anker SOLIX, Bluetti, EcoFlow, Jackery

We’re continuing our Best of Black Friday posts today with a look at the best current deals on power stations and their respective bundle options. Folks across the country and beyond have been steadily investing more and more in the industry for a vari...

World Of Warcraft Is Finally Getting Player Homes After 20 Years

Blizzard has announced that two decades after its release, World of Warcraft is finally going to let players build a home and live in it. The feature has long been requested by WoW players and now it’s finally coming in the game’s next expansion.Read m...

ArenaNet To Release ‘Godspawn’ Update for Guild Wars 2: Janthir Wilds on November 19, Featuring New 50-Player Titan Battle and More

Guild Wars 2: Janthir Wilds will receive the Godspawn update, adding a new 50-player boss battle, a new 10-player raid, and a legendary spear. Guild Wars 2: Janthir Wilds is getting the first major update "Godspawn" on November 19th, expanding the story with new story chapters The MMORPG Guild Wars 2 by ArenaNet is receiving its first major update for the Janthir Wilds expansion soon. It's the first of three major updates, and it'll land on November 19. The update will add new content to the game for the players. The Janthir Wilds expansion DLC was released in August this year, […]

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]

Eli Lilly and Company’s Weight Loss Drug Zepbound Approved by FDA; Will Be Available at $1,060 Per 6 Doses

The GLP-1 phenomenon is truly on the role, particularly in the US. Now, Eli Lilly and Company has moved one step closer to realizing the $100 billion annual sales potential for GLP-1 drugs by winning a key FDA approval. Eli Lilly and Company's Mounjaro (Tirzepatide) injections treat type-2 diabetes as well as obesity by targeting two hormones – Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) – to control blood sugar levels. Retatutide, another offering by Eli Lilly and Company, is currently undergoing clinical trials and supposedly offers superior results by targeting three different hunger-regulating hormones: GLP-1, GIP, and Glucagon. As […]

Wall Street is Downgrading Fitness Stocks Such as Peloton and Mooning Over GLP-1 Drug Makers Such as Eli Lilly and Company (LLY)

The stock market is currently undergoing a thematic shift, one that favors weight loss drug manufacturers such as Eli Lilly and Company (LLY) over fitness-related names such as Peloton (PTON). Akin to a stone rolling down a hill, gathering momentum with each turn, such shifts represent generational wealth-making opportunities on the back of accelerating trends, as was witnessed when Netflix ushered in the age of content streaming or when Tesla popularized EVs as a crucial ingredient in combatting climate change. Eli Lilly and Company (LLY) Vs. Peloton (PTON) Eli Lilly and Company's Mounjaro injections treat type-2 diabetes as well as […]

GLP-1 Effect: Eli Lilly and Company (LLY) Smashes Q3 2023 Revenue Expectations on Weight Loss Drug Tailwind

The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Co...

As the Quest for a Miracle Weight-Loss Drug Continues, Eli Lilly and Company Seems to Have an Edge Over Novo Nordisk’s Ozempic

Americans are among the least healthy first-world citizens, partly due to the fact that over 42 percent of the adults in the US suffer from obesity – a condition that […]

Written by Rohail Saleem

Tag: Eli Lilly and Company

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]

Eli Lilly and Company’s Weight Loss Drug Zepbound Approved by FDA; Will Be Available at $1,060 Per 6 Doses

The GLP-1 phenomenon is truly on the role, particularly in the US. Now, Eli Lilly and Company has moved one step closer to realizing the $100 billion annual sales potential for GLP-1 drugs by winning a key FDA approval. Eli Lilly and Company's Mounjaro (Tirzepatide) injections treat type-2 diabetes as well as obesity by targeting two hormones – Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) – to control blood sugar levels. Retatutide, another offering by Eli Lilly and Company, is currently undergoing clinical trials and supposedly offers superior results by targeting three different hunger-regulating hormones: GLP-1, GIP, and Glucagon. As […]

Wall Street is Downgrading Fitness Stocks Such as Peloton and Mooning Over GLP-1 Drug Makers Such as Eli Lilly and Company (LLY)

The stock market is currently undergoing a thematic shift, one that favors weight loss drug manufacturers such as Eli Lilly and Company (LLY) over fitness-related names such as Peloton (PTON). Akin to a stone rolling down a hill, gathering momentum with each turn, such shifts represent generational wealth-making opportunities on the back of accelerating trends, as was witnessed when Netflix ushered in the age of content streaming or when Tesla popularized EVs as a crucial ingredient in combatting climate change. Eli Lilly and Company (LLY) Vs. Peloton (PTON) Eli Lilly and Company's Mounjaro injections treat type-2 diabetes as well as […]

GLP-1 Effect: Eli Lilly and Company (LLY) Smashes Q3 2023 Revenue Expectations on Weight Loss Drug Tailwind

The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Co...

As the Quest for a Miracle Weight-Loss Drug Continues, Eli Lilly and Company Seems to Have an Edge Over Novo Nordisk’s Ozempic

Americans are among the least healthy first-world citizens, partly due to the fact that over 42 percent of the adults in the US suffer from obesity – a condition that […]

Written by Rohail Saleem

Recent articles

spot_img